59072 Federal Register / Vol. 70, No. 195 / Tuesday, October 11, 2005 / Notices 

To do so, a public education and 

awareness campaign will be launched to 

bring about changes in beliefs and social 

norms among target audiences 

(consumers: women aged 40–60, 

healthcare practitioners: nurse 

practitioners and physician assistants) 

that CFS is a diagnosable and treatable 

physical illness. 

Although considerable research will 

be done to ensure that campaign 

themes, messages, and materials are 

effective, there is no way to test the 

impact of the campaign on the target 

audience other than to conduct baseline 

and follow-up surveys. These surveys 

will measure not only the level of 

awareness created by the campaign, but 

will measure change in key knowledge, 

attitudes and beliefs about CFS among 

the target audiences. There is no cost to 

respondents other than their time. 

ESTIMATE OF ANNUALIZED BURDEN HOURS

Respondents Instrument Number of 

respondents 

Number of 

responses 

per respondent 

Response 

burden per 

respondent 

(in hours) 

Total annual 

burden 

(in hours) 

Consumers (Women, 40–60 years of age) Pre-program survey ................................. 400 1 10/60 67 

Consumers (Women, 40–60 years of age) Post-program survey ............................... 400 1 10/60 67 

Physician Assistants .................................. Pre-program survey ................................. 200 1 10/60 33 

Physician Assistants .................................. Post-program survey ............................... 200 1 10/60 33 

Nurse Practitioners .................................... Pre-program survey ................................. 200 1 10/60 33 

Nurse Practitioners .................................... Post-program survey ............................... 200 1 10/60 33 

Total ................................................... .................................................................. .................... .................... .................... 266 

Dated: October 4, 2005. 

Betsey Dunaway, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 05–20323 Filed 10–7–05; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2004N–0526] 

Agency Information Collection 

Activities; Announcement of Office of 

Management and Budget Approval; 

Guidance for Industry: Fast Track Drug 

Development Programs—Designation, 

Development, and Application Review 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a collection of information entitled 

‘‘Guidance for Industry: Fast Track Drug 

Development Programs—Designation, 

Development, and Application Review’’

has been approved by the Office of 

Management and Budget (OMB) under 

the Paperwork Reduction Act of 1995. 

FOR FURTHER INFORMATION CONTACT: 

Jonna Capezzuto, Office of Management 

Programs (HFA–250), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–827–4659. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of June 7, 2005 (70 FR 

33177), the agency announced that the 

proposed information collection had 

been submitted to OMB for review and 

clearance under 44 U.S.C. 3507. An 

agency may not conduct or sponsor, and 

a person is not required to respond to, 

a collection of information unless it 

displays a currently valid OMB control 

number. OMB has now approved the 

information collection and has assigned 

OMB control number 0910–0389. The 

approval expires on August 31, 2008. A 

copy of the supporting statement for this 

information collection is available on 

the Internet at http://www.fda.gov/ 

ohrms/dockets. 

Dated: October 3, 2005. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

[FR Doc. 05–20305 Filed 10–7–05; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2005N–0083] 

Agency Information Collection 

Activities; Announcement of Office of 

Management and Budget Approval; 

General Licensing Provisions: 

Biologics License Application, 

Changes to an Approved Application, 

Labeling, Revocation and Suspension, 

and Forms FDA 356h and 2567 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a collection of information entitled 

‘‘General Licensing Provisions: 

Biologics License Application, Changes 

to an Approved Application, Labeling, 

Revocation and Suspension, and Forms 

FDA 356h and 2567’’ has been approved 

by the Office of Management and 

Budget (OMB) under the Paperwork 

Reduction Act of 1995. 

FOR FURTHER INFORMATION CONTACT: 

Jonna Capezzuto, Office of Management 

Programs (HFA–250), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–827–4659. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of July 21, 2005 (70 FR 

42068), the agency announced that the 

proposed information collection had 

been submitted to OMB for review and 

clearance under 44 U.S.C. 3507. An 

agency may not conduct or sponsor, and 

a person is not required to respond to, 

a collection of information unless it 

displays a currently valid OMB control 

number. OMB has now approved the 

information collection and has assigned 

OMB control number 0910–0338. The 

approval expires on September 30, 

2008. A copy of the supporting 

statement for this information collection 

is available on the Internet at http:// 

www.fda.gov/ohrms/dockets. 

Dated: October 3, 2005. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

[FR Doc. 05–20306 Filed 10–7–05; 8:45 am] 

BILLING CODE 4160–01–S